What is Gilead Sciences's market cap?

Gilead Sciences (GILD) has a market capitalization of $168.63B and trades on NASDAQ.

What is Gilead Sciences's revenue and profitability?

Gilead Sciences generated $29.7B in trailing twelve-month revenue with net income of $9.2B, representing a net margin of 31.0%. Gross margin stands at 79.4%, with free cash flow of $10.2B. These figures are based on the Q1 2026 filing.

Who are Gilead Sciences's competitors?

Gilead Sciences's key competitors include Bristol-Myers Squibb, Assembly Biosciences, Inc, Merck & Co., Inc., and others. These companies compete in similar markets and product categories.

Who does Gilead Sciences partner with?

Gilead Sciences's notable partners include Merck & Co., Inc., Arcellx, Inc., Arcus Biosciences, Inc., and others.

What subsidiaries does Gilead Sciences have?

Gilead Sciences's subsidiaries include Asegua Therapeutics LLC, Kite Pharma.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in United States of America and employs approximately 18,000 people. It has been publicly traded since 1992.

Gilead Sciences

GILD

Gilead Sciences is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for life-threatening diseases.

Market cap

$168.63B+21.3%

Revenue$29.7B+3.5%

Net income$9.2B+54.5%

Free cash flow$10.2B+3.9%

EPS (diluted)$7.34+54.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$7.0BBeat by $46.6M EPS$2.03Beat by $0.12

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$7.4B

EPS estimate-$7.14

Financials

Q1 2026

Income statement

See full

Revenue$7.0B+4.4%

Gross profit$5.5B+7.6%

Operating income$2.6B+15.6%

Net income$2.0B+53.7%

EPS (diluted)$1.61+54.8%

Balance sheet

See full

Cash & equivalents$7.6B-3.8%

Total debt$22.2B-11.1%

Total equity$23.5B+22.7%

Total assets$56.3B-0.3%

Cash flow

See full

Operating cash flow$2.5B+44.8%

CapEx$117.0M+12.5%

Free cash flow$2.4B+46.8%

Valuation & ratios

Valuation

See full

Market cap$168.63B+21.3%

Enterprise value$183.18B+15.3%

P/E18.3×-3.7×

P/S5.7×+0.9×

Profitability

See full

Gross margin79.4%+1.1pp

Operating margin34.9%+6.3pp

Net margin31%+10.2pp

FCF margin34.4%+0.1pp

Returns & leverage

See full

Return on equity43.2%+10.7pp

Debt / equity0.9×-0.4×

Current ratio2×+0.6×

Segments

By product

See full

Biktarvy$3.4B+6.7%

Descovy$807.0M+37.7%

Trodelvy$402.0M+37.2%

Yescarta$332.0M-14.0%

Sofosbuvir/Velpatasvir$283.0M-18.2%

By geography

See full

Europe$1.1B+5.5%

Rest of World$889.0M-2.8%

Competitors

By market cap

AbbVie$446.54B+33.6%

Merck & Co.$311.17B+53.1%

Gilead Sciences$168.63B+21.3%

Bristol-Myers Squibb$117.50B+23.1%

Vir Biotechnology, Inc.$1.8B+135%

Assembly Biosciences$569.3M+311%

Enanta Pharmaceuticals$421.3M+150%

HIN

Vyome Holdings, Inc.$14.9M—

By revenue growth

Vir Biotechnology, Inc.+214%

Assembly Biosciences+121%

AbbVie+9.5%

Gilead Sciences+3.5%

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

By net margin

Gilead Sciences30.99%+10.2pp

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

AbbVie5.79%-1.5pp

Assembly Biosciences-103.65%+72.5pp

Vir Biotechnology, Inc.-675.96%+2,093pp

Profile

Gilead Sciences is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for life-threatening diseases. The company's core value proposition centers on transforming care in therapeutic areas with high unmet medical needs, particularly virology, oncology, and inflammation. Its primary revenue drivers include a robust portfolio of antiretroviral therapies for HIV and advanced treatments for viral hepatitis and cancer.

Competitive position

Gilead holds a dominant market position in HIV treatment and is a significant player in the CAR T-cell therapy and oncology markets.

GeographiesUnited States, Europe, International

Customer segmentsHealthcare providers, Pharmaceutical wholesalers, Government payers, Private insurers

Business modelR&D-driven drug development, Product manufacturing and sales, Intellectual property licensing

SuppliersContract manufacturing organizations (CMOs), Contract research organizations (CROs), Raw material suppliers, Contract testing laboratories (CTLs)

CustomersPharmaceutical wholesalers, Specialty distributors, Hospitals, Retail pharmacies, Government health programs

CountryUnited States of America

Listed1992

Employees18.0K

CEODaniel O'Day

SectorHealthcare

IndustryDrug Manufacturers - General

Websitegilead.com

FilingsSEC EDGAR

Ask your AI about Gilead Sciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gilead Sciences's market cap?: Gilead Sciences (GILD) has a market capitalization of $168.63B and trades on NASDAQ.
What is Gilead Sciences's revenue and profitability?: Gilead Sciences generated $29.7B in trailing twelve-month revenue with net income of $9.2B, representing a net margin of 31.0%. Gross margin stands at 79.4%, with free cash flow of $10.2B. These figures are based on the Q1 2026 filing.
Who are Gilead Sciences's competitors?: Gilead Sciences's key competitors include Bristol-Myers Squibb, Assembly Biosciences, Inc, Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
Who does Gilead Sciences partner with?: Gilead Sciences's notable partners include Merck & Co., Inc., Arcellx, Inc., Arcus Biosciences, Inc., and others.
What subsidiaries does Gilead Sciences have?: Gilead Sciences's subsidiaries include Asegua Therapeutics LLC, Kite Pharma.
Where is Gilead Sciences headquartered?: Gilead Sciences is headquartered in United States of America and employs approximately 18,000 people. It has been publicly traded since 1992.